New radioactive therapy shows promise for tough prostate cancers
NCT ID NCT04597411
First seen May 21, 2026 · Last updated May 26, 2026 · Updated 1 time
Summary
This early-stage study tests a radioactive drug called 225Ac-PSMA-617 in men with advanced prostate cancer that has stopped responding to hormone therapy. The goal is to find a safe dose and see if it can shrink tumors, even in men who have already received a similar treatment. About 101 men from multiple countries will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATIC NEOPLASMS, CASTRATION-RESISTANT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
St. Vincent's Hospital Research Office-Translational Research Center
Darlinghurst, Australia
-
Steve Biko Hospital-Department of Nuclear Medicine
Pretoria, South Africa
Conditions
Explore the condition pages connected to this study.